https://www.thebodypro.com/category/fosamprenavir-lexiva-telzir

Fosamprenavir (Lexiva, Telzir)

The Latest

Promo Image
News

Fosamprenavir Pediatric Dosing Approved in U.S. for Ages 4 Weeks to <6 Years

On 27 April 2012, the Food and Drug Administration approved dosing recommendations for use of fosamprenavir (Lexiva) oral suspension in pediatric patients.

Data submitted to FDA included three studies to support a new dosing regimen for fosamprenavi...

By HIV i-Base
Promo Image
News

Pharmacokinetics of Darunavir and Fosamprenavir in Pregnancy

Physiological changes in pregnancy can affect drug disposition. Plasma concentrations of several PIs -- including lopinavir, atazanavir and saquinavir -- currently prescribed to HIV-positive pregnant women, are decreased during this period. Pharmacok...

By Polly Clayden
Promo Image
News

FDA: HIV Drug Lexiva Label to Warn of Cholesterol Increases

GlaxoSmithKline PLC has written to doctors regarding label changes in its HIV drug Lexiva. The letter, which the Food and Drug Administration posted on its Web site Thursday, warns of increases in cholesterol levels and discusses a "potential" increa...

By CDC National Prevention Information Network
Promo Image
News

GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S.

Research Triangle Park -- GlaxoSmithKline [NYSE: GSK] announced today the launch of a new Patient Savings Card designed to help eligible patients improve compliance with their HIV regimens by reducing their out-of-pocket expenses for GSK HIV medica...

By GlaxoSmithKline
Promo Image

Labeling Update for Lexiva (Fosamprenavir)

The Lexiva (fosamprenavir) label was recently updated to include new drug-drug interaction information regarding phenytoin (an anticonvulsant) and paroxetine (an antidepressant).

Details of the newly added information are contained in the attached P...

By U.S. Food and Drug Administration
Promo Image
News

New Dosing Regimen for Fosamprenavir Approved: Ritonavir Dose Reduced

On October 12, 2007, the Food and Drug Administration (FDA) approved a supplemental new drug application for Lexiva (fosamprenavir calcium; FPV) Oral Tablets, adding a new indication for once-daily dosing of 1400 mg of Lexiva with 100 mg ritonavir fo...

By U.S. Food and Drug Administration
Promo Image
News

Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S.

Dear Healthcare Provider:

This letter is intended to inform you that GlaxoSmithKline will be discontinuing the sale of Agenerase Oral Solution and 50 mg Capsules in the US by the end of October 2007. This action is not the result of any safety or ef...

By GlaxoSmithKline
Promo Image
Conference Coverage

Fosamprenavir Efficacy and Safety on Par With Other PIs, With No Gender-Based Differences

Fosamprenavir (FPV, 908, Lexiva, Telzir) is a potent protease inhibitor that was approved by the Food and Drug Administration in October 2003. Several studies have documented the safety and efficacy of once-daily fosamprenavir boosted with ritonavir ...

By Mark Wainberg, Ph.D.
Promo Image
Conference Coverage

Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy

Current U.S. Department of Health and Human Services guidelines1 recommend lopinavir/ritonavir (LPV/r, Kaletra) in combination with lamivudine (3TC, Epivir) or emtricitabine (FTC, Emtriva) and zidovudine (AZT, Retrovir) as a first-line regimen for tr...

By Edwin DeJesus, M.D.
Promo Image
News

Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used

For HIV-infected patients with protease inhibitor (PI) resistance, there has been a lot of good news of late with the advent of PIs such as tipranavir (TPV, Aptivus) and TMC114. There also remains continued interest in the use of dual PIs for the tre...

By Benjamin Young, M.D., Ph.D.